A Large Genome-Wide Association Study of Age-Related Macular Degeneration Highlights Contributions of Rare and Common Variants

A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants

Iris Heid, Gonçalo Abecasis, Sudha Iyengar and colleagues report the results of a large genome-wide association meta-analysis of macular degeneration based on over 43,000 subjects. They identify 16 new risk loci, including some very rare coding variants. Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 1…

Fixing problems in cholesterol metabolism could stave off a leading cause of blindness

A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression of age-related macular degeneration, a leading cause of blindness in people over age 50. The study appears in the journal Nature Communications.

Hadley and Notal Vision Partner to Empower Patients With Vision Loss Through Education and Leading Technology

Hadley and Notal Vision announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision’s ForeseeHome and SCANLY Home OCT monitoring programs with Hadley’s specialized programming, including Living with Macular Degeneration workshop series (hadleyhelps.org/workshops/living-with-macu…

Next-generation retinal disease treatments: Advancing care in nAMD and DME

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Breakthrough eye drops reverse vision loss from age-related macular degeneration

Toll-like receptors, or TLRs, are the immune system’s early warning sensors. They detect microbial invaders and damage signals, helping the body mount a defense. But when TLR signaling veers off course, the results can be disastrous—triggering chronic inflammation, infections that linger, or autoimmune flare-ups. These issues have pushed scientists to explore new solutions. One bold approach involves small TLR-targeting peptides. By fine-tuning …